Substrate specificity, inhibitor selectivity and structure-function relationships of aldo-keto reductase 1B15: A novel human retinaldehyde reductase

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Giménez Dejoz, Joan ^a   Koláø, Michal H ^b,c   Ruiz, Francesc X ^d   Crespo, Isidro ^a   Cousido Siah, Alexandra ^d   Podjarny, Alberto ^d   Barski, Oleg A ^e   Fanfrlík, Jindøich ^b   Parés, Xavier ^a   Farrés, Jaume ^a   Porté, Sergio ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

^d CNRS   (France)

^e University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLACETONE; ALDO KETO REDUCTASE 1B1; ALDO KETO REDUCTASE 1B10; ALDO KETO REDUCTASE 1B15; DETERGENT; EPALRESTAT; GLYCERALDEHYDE; KETONE; LITHOCHOLIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OLEANOLIC ACID; OXIDOREDUCTASE; RETINAL; RETINOID; SARKOSYL; SULINDAC; TOLRESTAT; UNCLASSIFIED DRUG; 9-CIS-RETINAL; AKR1B10 PROTEIN, HUMAN; AKR1B15 PROTEIN, HUMAN; ALDEHYDE REDUCTASE; ENZYME INHIBITOR; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CATALYSIS; CATALYTIC EFFICIENCY; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; ENZYME KINETIC ASSAY; ENZYME PURIFICATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR WEIGHT; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; GENETICS; KINETICS; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; STRUCTURAL HOMOLOGY;

ALDEHYDE REDUCTASE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CATALYTIC DOMAIN; ENZYME INHIBITORS; HUMANS; KINETICS; MODELS, MOLECULAR; OXIDOREDUCTASES ACTING ON ALDEHYDE OR OXO GROUP DONORS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; RETINALDEHYDE; STRUCTURAL HOMOLOGY, PROTEIN; SUBSTRATE SPECIFICITY;

EID: 84941671000     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134506     Document Type: Article

References (71)

1. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol. 2007; 47: 263-292. PMID: 16970545
2. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 2008; 40: 553-624. PMID: 18949601
3. Ruiz FX, Gallego O, Ardèvol A, Moro A, Domínguez M, Alvarez S, et al. Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem Biol Interact. 2009; 178:171-177. doi: 10.1016/j.cbi.2008.10.027 PMID: 19014918
4. Matsunaga T, Wada Y, Endo S, Soda M, El-Kabbani O, Hara A. Aldo-Keto Reductase 1B10and Its Role in Proliferation Capacity of Drug-Resistant Cancers. Front Pharmacol. 2012; 3: 5. doi: 10.3389/fphar.2012.00005 PMID: 22319498
5. Ruiz FX, Moro A, Gallego O, Ardèvol A, Rovira C, Petrash JM, et al. Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde. Chem Biol Interact. 2011; 191:199-205. doi: 10.1016/j.cbi.2011.02.007 PMID: 21329680
6. Salabei JK, Li X-P, Petrash JM, Bhatnagar A, Barski OA. Functional expression of novel human and murine AKR1B genes. Chem Biol Interact. 2011; 191:177-184. doi: 10.1016/j.cbi.2011.01.020 PMID: 21276782
7. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008; 9: 14-36. PMID: 18220710
8. Ma J, Luo DX, Huang C, Shen Y, Bu Y, Markwell S, et al. AKR1B10overexpression in breast cancer: association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. Int J Cancer. 2012; 131: 862-871.
9. Tammali R, Reddy ABM, Saxena A, Rychahou PG, Evers BM, Qiu S, et al. Inhibition of aldose reductase prevents colon cancer metastasis. Carcinogenesis. 2011; 32:1259-1267. doi: 10.1093/carcin/bgr102 PMID: 21642355
10. Endo S, Matsunaga T, Kuwata K, Zhao H-T, El-Kabbani O, Kitade Y, et al. Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. Bioorg Med Chem. 2010; 18: 2485-2490. doi: 10.1016/j.bmc.2010.02.050 PMID: 20304656
11. Chatzopoulou M, Alexiou P, Kotsampasakou E, Demopoulos VJ. Novel aldose reductase inhibitors: a patent survey (2006-present). Expert Opin Ther Pat. 2012; 22:1303-1323. doi: 10.1517/13543776. 2012.726615 PMID: 22998509
12. Pathania S, Randhawa V, Bagler G. Prospecting for novel plant-derived molecules of Rauvolfia serpentina as inhibitors of Aldose Reductase, a potent drug target for diabetes and its complications. PLoS One. 2013; 8: e61327. doi: 10.1371/journal.pone.0061327 PMID: 23613832
13. Soda M, Hu D, Endo S, Takemura M, Li J, Wada R, et al. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10. Eur J Med Chem. 2012; 48: 321-329. doi: 10.1016/j.ejmech.2011.12.034 PMID: 22236472
14. Zhang L, Zhang H, Zheng X, Zhao Y, Chen S, Chen Y, et al. Structural basis forthe inhibition of AKR1B10 by caffeic acid phenethyl ester (CAPE). Chem Med Chem. 2014; 9: 706-709. doi: 10.1002/cmdc.201300455 PMID: 24436249
15. Cousido-Siah A, Ruiz FX, Mitschler A, Porté S, de Lera AR, Martín MJ, et al. Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design. Acta Crystallogr D Biol Crystallogr. 2014; 70: 889-903. doi: 10.1107/S1399004713033452 PMID: 24598757
16. Weber S, Salabei JK, MöllerG, Kremmer E, Bhatnagar A, Adamski J, et al. Aldo-Keto Reductase 1B15 (AKR1B15): a Mitochondrial Human Aldo-Keto Reductase with Activity towards Steroids and 3-Keto-acyl-CoA Conjugates. J Biol Chem. 2015; 209: 6531-6545
17. Hackett NR, Butler MW, Shaykhiev R, Salit J, Omberg L, Rodriguez-Flores JL, et al. RNA-Seq quantification of the human small airway epithelium transcriptome. BMC Genomics. 2012; 13: 82. doi: 10. 1186/1471-2164-13-82 PMID: 22375630
18. Constantinescu S, Hecht K, Sobotzki N, Erzinger MM, Bovet C, Shay JW, et al. Transcriptomic responses of cancerous and noncancerous human colon cells to sulforaphane and selenium. Chem Res Toxicol. 2014; 27: 377-386. doi: 10.1021/tx400427t PMID: 24383545
19. Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker EJ, et al. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med. 2012; 4: 118ra10. doi: 10.1126/scitranslmed.3003310 PMID: 22277967
20. Reumers J, De Rijk P, Zhao H, Liekens A, Smeets D, Cleary J, et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol. 2012; 30: 61-8.
21. Yashin AI, Wu D, Arbeev KG, Ukraintseva SV. Joint influence of small-effect genetic variants on human longevity. Aging. 2010; 2: 612-620. PMID: 20834067
22. De Marco A, Deuerling E, Mogk A, Tomoyasu T, Bukau B. Chaperone-based procedure to increase yields of soluble recombinant proteins produced in E. coli. BMC Biotechnol. 2007; 7: 32. PMID: 17565681
23. Gallego O, Ruiz FX, Ardèvol A, Domínguez M, Alvarez R, de Lera AR, et al. Structural basis forthe high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA. 2007; 104: 20764-20769. PMID: 18087047
24. Larroy C, Fernandez MR, Gonzalez E, Parés X, Biosca JA. Characterization of the Saccharomyces cerevisiae YMR318C (ADH6) gene product as a broad specificity NADPH-dependent alcohol dehydrogenase: relevance in aldehyde reduction. Biochem J. 2002; 172:163-172.
25. Gallego O, Belyaeva OV, Porté S, Ruiz FX, Stetsenko AV, Shabrova EV, et al. Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldo-keto reductases with retinoids. Biochem J. 2006; 399:101-109. PMID: 16787387
26. Kuksa V, Imanishi Y, Batten M, Palczewski K, Moise AR. Retinoid cycle in the vertebrate retina: experimental approaches and mechanisms of isomerization. Vision Res. 2003; 43: 2959-2981. PMID: 14611933
27. Belyaeva OV, Korkina OV, Stetsenko AV, Kim T, Nelson PS, Kedishvili NY. Biochemical properties of purified human retinol dehydrogenase 12(RDH12): catalytic efficiency toward retinoids and C9 aldehydes and effects of cellular retinol-binding protein type I (CRBPI) and cellular retinaldehyde-binding protein (CRALBP) on the oxidation and reduction of retinoids. Biochemistry. 2005; 44: 7035-7047. PMID: 15865448
28. Canutescu AA, Shelenkov AA, Dunbrack RL. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci. 2003; 12: 2001-2014. PMID: 12930999
29. Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013; 29: 845-854. doi: 10.1093/bioinformatics/btt055 PMID: 23407358
30. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins. 2006; 65: 712-725. PMID: 16981200
31. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins. 2010; 78:1950-1958. doi: 10.1002/prot.22711 PMID: 20408171
32. Holmberg N, Ryde U, Bülow L. Redesign of the coenzyme specificity in L-lactate dehydrogenase from bacillus stearothermophilus using site-directed mutagenesis and media engineering. Protein Eng. 1999; 12: 851-856. PMID: 10556245
33. Hawkins GD, Cramer CJ, Truhlan DG. Parametrized Models of Aqueous Free Energies of Solvation Based on Pairwise Descreening of Solute Atomic Charges from a Dielectric Medium. J Phys Chem. 1996; 100:19824-19839.
34. Seeliger D, Haas J, de Groot BL. Geometry-based sampling of conformational transitions in proteins. Structure. 2007; 15:1482-1492. PMID: 17997973
35. De Groot BL, van Aalten DM, Scheek RM, Amadei A, Vriend G, Berendsen HJ. Prediction of protein conformational freedom from distance constraints. Proteins. 1997;29:240-251. PMID: 9329088
36. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. International Union of Crystallography; 1993; 26: 283-291.
37. Eisenberg D, Lüthy R, Bowie JU. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol. 1997; 277: 396-404. PMID: 9379925
38. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit. 9:1-5. PMID: 8723313
39. Porté S, Ruiz FX, Giménez J, Molist I, Alvarez S, DomínguezM, et al. Aldo-keto reductases in retinoid metabolism: search for substrate specificity and inhibitor selectivity. Chem Biol Interact. 2013; 202: 186-194. doi: 10.1016/j.cbi.2012.11.014 PMID: 23220004
40. Ezác J, Fanfrlík J, Salahub D, Hobza P. Semiempirical Quantum Chemical PM6 Method Augmented by Dispersion and H-Bonding Correction Terms Reliably Describes Various Types of Noncovalent Complexes. J Chem Theory Comput. 2009; 5:1749-1760.
41. Klamt A, Schüürmann G. COSMO: a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. J Chem Soc. 1993; 2: 799-805.
42. Lepšík M, ezác J, Kolár M, Pecina A, Hobza P, Fanfrlík J. The Semiempirical Quantum Mechanical Scoring Function for In Silico Drug Design. Chempluschem. 2013; 78: 921-931.
43. Fanfrlík J, Koláf M, Kamlar M, Hurný D, Ruiz FX, Cousido-Siah A, et al. Modulation of aldose reductase inhibition by halogen bond tuning. ACS Chem Biol. 2013; 8: 2484-2492. doi: 10.1021/cb400526n PMID: 23988122
44. Benkert P, Tosatto SCE, Schomburg D. QMEAN: A comprehensive scoring function for model quality assessment. Proteins. 2008; 71: 261-277. PMID: 17932912
45. Durrant JD, de Oliveira CAF, McCammon JA. POVME: an algorithm for measuring binding-pocket volumes. J Mol Graph Model. 2011; 29: 773-776. doi: 10.1016/j.jmgm.2010.10.007 PMID: 21147010
46. Tao H, Liu W, Simmons BN, Harris HK, Cox TC, Massiah M a. Purifying natively folded proteins from inclusion bodies using sarkosyl, Triton X-100, and CHAPS. Biotechniques. 2010; 48: 61-64. doi: 10. 2144/000113304 PMID: 20078429
47. Pastel E, Pointud J-C, Volat F, Martinez A, Lefrançois-Martinez A-M. Aldo-Keto Reductases 1B in Endocrinology and Metabolism. Front Pharmacol. 2012; 3:148. doi: 10.3389/fphar.2012.00148 PMID: 22876234
48. Ruiz FX, Porté S, Gallego O, Moro A, Ardèvol A, Del Río-Espínola A, et al. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily. Biochem J. 2011; 440: 335-344. doi: 10.1042/BJ20111286 PMID: 21851338
49. Crosas B, Cederlund E, Torres D, Jornvall H, Farrés J, Parés X. A vertebrate aldo-keto reductase active with retinoids and ethanol. J Biol Chem. 2001; 276:19132-19140. PMID: 11278684
50. Verma M, Martin HJ, Haq W, O'Connor TR, Maser E, Balendiran GK. Inhibiting wild-type and C299S mutant AKR1B10; ahomologueof aldose reductase upregulated in cancers. Eur J Pharmacol. 2008; 584: 213-221. doi: 10.1016/j.ejphar.2008.01.036 PMID: 18325492
51. Ruiz FX, Cousido-Siah A, Mitschler A, Farrés J, Parés X, Podjarny A. X-ray structure of the V301Laldo-keto reductase 1B10 complexed with NADP+and the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity. Chem Biol Interact. 2013; 202:178-185. doi: 10.1016/j. cbi.2012.12.013 PMID: 23295227
52. Zhang L, Zhang H, Zhao Y, Li Z, Chen S, Zhai J, et al. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: roleofTrp112(Trp111). FEBS Lett. 2013; 587: 3681-3686. doi: 10.1016/j.febslet.2013.09.031 PMID: 24100137
53. Sundaram K, Dhagat U, Endo S, Chung R, Matsunaga T, Hara A, et al. Structure of rat aldose reduc-tase-like protein AKR1B14 holoenzyme: Probing the role of His269 in coenzyme binding by site-directed mutagenesis. Bioorg Med Chem Lett. 2011; 21: 801-804. doi: 10.1016/j.bmcl.2010.11.086 PMID: 21168333
54. Urzhumtsev A, Tête-Favier F, Mitschler A, Barbanton J, Barth P, Urzhumtseva L, et al. A "specificity" pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure. 1997; 5: 601-612. PMID: 9195881
55. Kokkinidis M, Glykos NM, Fadouloglou VE. Protein Flexibility and Enzymatic Catalysis. Adv Protein Chem Struct Biol. 2012. pp. 181-218. doi: 10.1016/B978-0-12-398312-1.00007-X PMID: 22607756
56. Kedishvili NY. Enzymology of retinoic acid biosynthesis and degradation. J Lipid Res. 2013; 54:1744-1760. doi: 10.1194/jlr.R037028 PMID: 23630397
57. Belyaeva OV, Korkina OV, Stetsenko AV, Kedishvili NY. Human retinol dehydrogenase 13(RDH13) is a mitochondrial short-chain dehydrogenase/reductase with a retinaldehyde reductase activity. FEBS J. 2008; 275:138-147. PMID: 18039331
58. Ruiz FX, Porté S, Parés X, Farrés J. Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling. Front Pharmacol. 2012; 3: 58. doi: 10.3389/fphar.2012.00058 PMID: 22529810
59. Palczewski G, Amengual J, Hoppel CL, von Lintig J. Evidence for compartmentalization of mammalian carotenoid metabolism. FASEB J. 2014; 1-13. doi: 10.1096/fj.14-0101LTE
60. Jiang W, Napoli JL. The retinol dehydrogenase Rdh10 localizes to lipid droplets during acyl ester biosynthesis. J Biol Chem. 2013; 288: 589-597. doi: 10.1074/jbc.M112.402883 PMID: 23155051
61. Acin-Perez R, Hoyos B, Zhao F, Vinogradov V, Fischman Da, Harris Ra, et al. Control of oxidative phosphorylation by vitamin A illuminates a fundamental role in mitochondrial energy homoeostasis. FASEB J. 2010; 24: 627-636. doi: 10.1096/fj.09-142281 PMID: 19812372
62. Echtay KS, Brand MD. 4-hydroxy-2-nonenal and uncoupling proteins: an approach for regulation of mitochondrial ROS production. Redox Rep. 2007; 12: 26-29. PMID: 17263904
63. Zhong H, Yin H. Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: Focusing on mitochondria. Redox Biol. 2015; 4:193-199. doi: 10.1016/j.redox.2014.12.011 PMID: 25598486
64. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol. 1996; 3: 927-933. PMID: 8901870
65. Kimble-Hill AC, Parajuli B, Chen CH, Mochly-Rosen D, Hurley TD. Development of selective inhibitors for aldehyde dehydrogenases based on substituted indole-2, 3-diones. J Med Chem. 2014; 57: 714-722. doi: 10.1021/jm401377v PMID: 24444054
66. Endo S, Matsunaga T, Mamiya H, Ohta C, Soda M, Kitade Y, et al. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch Biochem Bio-phys. 2009; 487:1-9. doi: 10.1016/j.abb.2009.05.009 PMID: 19464995
67. Shen Y, Zhong L, Johnson S, Cao D. Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophiliccarbonyl compounds. Chem Biol Interact. 2011; 191:192-198. doi: 10.1016/j.cbi.2011.02.004 PMID: 21329684
68. Calam E, Porté S, Fernández MR, Farrés J, Parés X, Biosca JA. Biocatalytic production of alpha-hydroxy ketones and vicinal diols by yeast and human aldo-keto reductases. Chem Biol Interact. 2013; 202:195-203. doi: 10.1016/j.cbi.2012.12.006 PMID: 23295224
69. Kubiseski TJ, Flynn TG. Studies on human aldose reductase. Probing the roleof arginine 268 by site-directed mutagenesis. J Biol Chem. 1995; 270:16911-16917. PMID: 7622508
70. Ehrig T, Bohren KM, Prendergast FG, Gabbay KH. Mechanism of aldose reductase inhibition: binding of NADP+/NADPH and alrestatin-like inhibitors. Biochemistry. 1994; 33: 7157-7165. PMID: 8003482
71. Endo S, Matsunaga T, Soda M, Tajima K, Zhao H-T, El-Kabbani O, et al. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. Biol Pharm Bull. 2010; 33: 886-890. PMID: 20460771